Veristat

Tweet this page
<
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
>
Registration as it was on 21 Feb 2025
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

150,000€

Financial year: Jan 2024 - Dec 2024

Lobbyists (Full time equivalent)

1.25 Fte (3)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Veristat

    EU Transparency Register

    31442479070-19 First registered on 02 Jul 2012

    Goals / Remit

    Veristat LLC is the science-first full-service drug and biologic CRO and consultancy that integrates strategic planning, regulatory expertise, and clinical trial execution to rapidly advance the most complex or novel therapies. Our scientific experts design and conduct the global activities required for any clinical, regulatory, or commercialization program comprehensively and efficiently. 
    Veristat meets clients’ needs through every stage of the product lifecycle. Our team has a proven track record in specific areas of expertise & excellent understanding of products’ lifecycle.
    Public Affairs Services: Veristat advises organizations on engaging in the EU debate to shape regulatory & policy frameworks. Our team has extensive hands-on experience & proven success in supporting clients to contribute to EU healthcare laws & policies. Our services comprise strategic & operational public affairs support, intelligence, advocacy support & association management.

    Main EU files targeted

    - EU Pharmaceutical Strategy
    - European Health Union, HERA
    - Implementation of Medical Devices Regulation and In-vitro Diagnostics Regulation
    - Orphan Medicinal Products Regulation, Pediatric Regulation and their revision
    - Revision of the EU general pharmaceutical legislation
    - Incentives on medicinal products
    - Advanced Therapy Medicinal Products Regulation
    - Planned EU Biotech Act
    - Planned EU Critical Medicines Act
    - Europe’s Beating Cancer Plan
    - Clinical Trials Regulation and Clinical Trials Information System
    - European Medicines Agency policy on publication of
    clinical data for medicinal products for human use
    - Implementation of Regulation on Health Technology Assessment
    - Cross-border healthcare
    - EUnetHTA
    - EU pharmacovigilance system
    - EU personalized medicine activities such as use of '-omics' technologies in the development of personalized medicine
    - Access to Medicines
    - Shortages of medicinal products and medical devices
    - Horizon Europe
    - European Data Strategy, Artificial Intelligence and Cybersecurity
    - Data Governance Act and Data Act
    - Digital infrastructure and cybersecurity
    - Regulation on Artificial Intelligence
    - European Health Data Space
    - General Data Protection Regulation
    - European Green Deal
    - Circular Economy Action Plan
    - EU strategy for chemicals sustainability
    - Regulation on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
    - PFAS regulations
    - Planned Chemicals Industry Package
    - EU industrial strategy
    - Planned EU Clean Industrial Deal
    - EU Competitiveness Compass
    - Planned Single Market Strategy
    - Planned EU Innovation Act
    - Planned EU Research Area Act

    Address

    Head Office
    134 Turnpike RoadSuite 200
    Southborough MA 01772
    UNITED STATES
    EU Office
    Aeschenvorstadt 52
    Basel 4051
    SWITZERLAND

    Website

  • People

    Total lobbyists declared

    3

    Employment timeLobbyists
    50%2
    25%1

    Lobbyists (Full time equivalent)

    1.25

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Professional consultancies

  • Networking

    Affiliation

    SFL is a member of Medtech & Pharma Platform (MPP).

    SFL is a member of SWISS MEDTECH.

    SFL is a member of the Round Table on Antibiotics.

    SFL is a member of the British-Swiss Chamber of Commerce.

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Advances interests of their clients

    Closed financial year

    Jan 2024 - Dec 2024

    Lobbying costs for closed financial year

    150,000€

    Major contributions in closed year

    None declared

    Clients for closed financial year

    Clients list
    NameProposalAmount
    Medtech & Pharma Platform (MPP) Our work as leading the Secretariat covers widely all policies and legislation relevant to the combined products, i.e. products consisting of a combined use of a medicinal product, medical device or in vitro diagnostic, including those with a digital component. 100,000€ - 199,999€
    F. Hoffmann-La Roche Ltd Our work covers widely health policies and legislation in the European Union. In addition, policies and legislations impacting conditions applicable to the establishment and running of corporations are also covered. 50,000€ - 99,999€

    Clients for current financial year

    Clients list
    Name
    F. Hoffmann-La Roche Ltd

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    N/A

    Communication activities

    Veristat supports its clients with impact analysis and strategic communication advice on the dossiers and activities listed under ‘Main EU initiatives, policies and legislative files monitored by your organisation’. Veristat advises on internal organizational matters to help clients formulate aligned positions and speak with one voice to regulators, policymakers and other stakeholders.

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard